Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allakos Inc. stock logo
ALLK
Allakos
$0.33
$0.33
$0.22
$1.56
$29.74M0.151.22 million shsN/A
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$129.30
0.0%
$117.02
$73.04
$129.49
$8.35B0.891.39 million shs3.57 million shs
Evotec SE stock logo
EVTCY
Evotec
$4.07
-2.4%
$4.13
$14.22
$26.57
$1.34B0.982,407 shs29,351 shs
FibroGen, Inc stock logo
FGEN
FibroGen
$7.15
-2.7%
$6.97
$4.50
$38.25
$28.90M0.7476,133 shs59,782 shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$16.04
+0.4%
$14.92
$11.51
$21.50
$2.80B0.5294,291 shs28,642 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allakos Inc. stock logo
ALLK
Allakos
0.00%0.00%0.00%+2.72%-60.35%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
0.00%+0.80%+0.85%+59.95%+11.51%
Evotec SE stock logo
EVTCY
Evotec
-2.40%-3.10%-4.68%+27.99%-20.51%
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%+25.66%-7.29%+3.17%-68.34%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.00%+0.92%-9.48%+16.91%-3.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allakos Inc. stock logo
ALLK
Allakos
2.9411 of 5 stars
3.10.00.04.70.62.51.3
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.2222 of 5 stars
2.12.00.00.02.90.80.6
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/AN/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
4.7276 of 5 stars
3.34.00.04.73.83.30.6
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1.6191 of 5 stars
2.03.00.00.02.50.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allakos Inc. stock logo
ALLK
Allakos
2.25
Hold$2.00507.72% Upside
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.24
Hold$128.25-0.81% Downside
Evotec SE stock logo
EVTCY
Evotec
0.00
N/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
2.50
Moderate Buy$250.003,396.50% Upside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.00
Hold$19.0018.45% Upside

Current Analyst Ratings Breakdown

Latest BPMC, EVTCY, FGEN, ALLK, and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/13/2025
FibroGen, Inc stock logo
FGEN
FibroGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$250.00 ➝ $250.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/A$1.93 per shareN/A
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$508.82M16.41N/AN/A$4.70 per share27.51
Evotec SE stock logo
EVTCY
Evotec
$572.16M2.35$0.04 per share105.53$2.52 per share1.62
FibroGen, Inc stock logo
FGEN
FibroGen
$29.62M0.98N/AN/A($50.89) per share-0.14
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.44$0.29 per share55.84$4.43 per share3.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allakos Inc. stock logo
ALLK
Allakos
-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A198.92N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
Evotec SE stock logo
EVTCY
Evotec
$7.14M$0.419.93N/A20.85%16.02%7.81%N/A
FibroGen, Inc stock logo
FGEN
FibroGen
-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0010.99N/AN/AN/AN/A8/7/2025 (Estimated)

Latest BPMC, EVTCY, FGEN, ALLK, and HCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.54N/AN/AN/A$171.34 millionN/A
8/6/2025Q2 2025
Allakos Inc. stock logo
ALLK
Allakos
-$0.24N/AN/AN/AN/AN/A
8/5/2025Q2 2025
FibroGen, Inc stock logo
FGEN
FibroGen
-$0.09N/AN/AN/A$2.88 millionN/A
5/12/2025Q1 2025
FibroGen, Inc stock logo
FGEN
FibroGen
$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allakos Inc. stock logo
ALLK
Allakos
N/AN/AN/AN/AN/A
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Evotec SE stock logo
EVTCY
Evotec
N/AN/AN/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allakos Inc. stock logo
ALLK
Allakos
N/A
6.08
6.08
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Evotec SE stock logo
EVTCY
Evotec
0.53
2.57
2.50
FibroGen, Inc stock logo
FGEN
FibroGen
N/A
2.02
1.98
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70

Institutional Ownership

CompanyInstitutional Ownership
Allakos Inc. stock logo
ALLK
Allakos
84.64%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
Evotec SE stock logo
EVTCY
Evotec
N/A
FibroGen, Inc stock logo
FGEN
FibroGen
72.71%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%

Insider Ownership

CompanyInsider Ownership
Allakos Inc. stock logo
ALLK
Allakos
16.12%
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
Evotec SE stock logo
EVTCY
Evotec
N/A
FibroGen, Inc stock logo
FGEN
FibroGen
3.07%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allakos Inc. stock logo
ALLK
Allakos
19090.38 million74.94 millionOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Evotec SE stock logo
EVTCY
Evotec
4,200330.22 millionN/ANot Optionable
FibroGen, Inc stock logo
FGEN
FibroGen
5704.04 million3.92 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.32 million168.05 millionNot Optionable

Recent News About These Companies

HUTCHMED to Announce 2025 Half-Year Financial Results
HUTCHMED (China) Limited (HCM.L) - Yahoo Finance
HUTCHMED (China) Limited (HCM) - Yahoo Finance
Hutchmed introduces new share options and LTIP awards

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allakos stock logo

Allakos NASDAQ:ALLK

$0.33 0.00 (0.00%)
As of 05/15/2025

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$129.30 -0.03 (-0.02%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$129.30 0.00 (0.00%)
As of 07/11/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Evotec stock logo

Evotec OTCMKTS:EVTCY

$4.07 -0.10 (-2.40%)
As of 07/11/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

FibroGen stock logo

FibroGen NASDAQ:FGEN

$7.15 -0.20 (-2.72%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$7.30 +0.15 (+2.10%)
As of 07/11/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$16.04 +0.07 (+0.44%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$16.05 +0.01 (+0.06%)
As of 07/11/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.